Efficient expression of modified human papillomavirus 16 E6/E7 fusion protein and the antitumor efficacy in a mouse model

Biological and Pharmaceutical Bulletin

Volumn 27, Issue 3, 2004, Pages 303-307

  Zhou, Xiaoshan ^a   Qian, Xinlai ^a   Zhao, Qingzheng ^a   Lu, Yuanzhi ^a   Xiong, Maolin ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Cervical cancer; Human papillomavirus 16 (HPV16); Immunotherapy; Vaccine

Indexed keywords

PROTEIN E6; PROTEIN E7; VIRUS FUSION PROTEIN; CANCER VACCINE; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; HYBRID PROTEIN; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; ESCHERICHIA COLI; GENE CONSTRUCT; GENE EXPRESSION; GENETIC CODE; HUMAN PAPILLOMAVIRUS TYPE 16; MOUSE; NONHUMAN; POINT MUTATION; VIRUS CARCINOGENESIS; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CYTOTOXICITY; DISEASE MODEL; FEMALE; GENETICS; IMMUNIZATION; IMMUNOLOGY; PAPILLOMA VIRUS; SPLEEN; TIME; TUMOR CELL LINE; VIRUS INFECTION;

ANIMALS; BLOTTING, WESTERN; CANCER VACCINES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FEMALE; IMMUNIZATION; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; SPLEEN; TIME FACTORS; TUMOR VIRUS INFECTIONS;

EID: 4344676692     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.27.303     Document Type: Article

References (35)

1. Zur Hausan H., Biochem. Biophys. Acta, 1288, 55-78 (1996).
2. Walboomers J. M., Jacobs M. V., Manos M. M., Bosch F. X., Kumme J. A., Shah K. V., Snijdesr P. F., Peto J., Meijer C. L. M., Muňoz C. L. M., J. Pathol., 189, 12-19 (1999).
3. Crook T., Morgenstern J. P., Crawford L., Banks L., EMBO J., 8, 513-519 (1989).
4. Schwartz E., Freese V. K., Gissman L., Nature (London), 314, 111-114 (1985).
5. Chen L. P., Thomas E. K., Hu S. L., Haltom I., Hellstrom K. E., Proc. Natl. Acad. Sci. U.S.A., 88, 110-114 (1991).
6. Benton C., Shahidullah H., Hunter J. A. A., Papillomavirus Rep., 1, 323-326 (1992).
7. Aiba S., Rokugo M., Tagami H., Cancer, 58, 1246-1251 (1986).
8. Kadish A. S., Ho G. Y. F., Burk R. D., Wang Y., Romney S. L., Ledwidge R., Angeletti R. H., Cancer Res., 89, 1285-1293 (1997).
9. Evans E. M.-L., Man S., Evans A. S., Borysiewicz L. K., Cancer Res., 57, 2943-2950 (1997).
10. Daemen T., Rents J., Holtrop M., Wilschut J., Gene Therapy, 9, 85-94 (2002).
11. He Z., Wlazlo A. P., Kowalczyk D. W., Cheng J., Xiang Z. Q., Giles-Davis W., Ertl H. C. J., Virology, 48, 6-29 (2000).
12. Fernamdo G. J. P., Murray B., Zhou J., Frazer I. H., Clin. Exp. Immunol., 115, 397-403 (1999).
13. De Bruijn M. L. H., Schuurhuis D. H., Vierboom M. P. M., Vermeulen H., de Cock K. A. J., Omas M. D., Ressing M. E., Toebes M., Franken K. L. M. C., Drijfhout J.-W., Ottenhoff T. H. M., Offringa R., Melief C. J. M., Cancer Res., 58, 724-731 (1998).
14. Feltkamr M. C. W., Smits H. L., Vierboom M. P. M, Minaar R. P., Jongh B. M., Drijfhout M. J. W., Ter Schegget J., Melief C. J. M., Kast W. M., Europ. J. Immunol., 23, 2242-2249 (1993).
15. Feltkamr M. C. W., Vreugdenhil G. R., Vierboom M. P. M., Ras E., Van Der Burg S. H., Schegget J. T., Melief C. J. M., Kast W. M., Eur. J. Immunol., 25, 2638-2642 (1995).
16. Zhu X., Tommasinos M., Vousden K., Sadovnika D., Rappuoli R., Crawford I., Kast W., Melief C. J. M., Beverley P. C. L, Stauss H. J., Scand. J. Immunol., 42, 557-563 (1995).
17. Gao L., Chain B., Sinclair C., Crawford L., Zhou J., Morris J., Zhu X., Stauss H., J. Gen. Virol., 75, 157-164 (1994).
18. Chu N. R., Wu H. B., Wu T.-C., Boux L. J., Siegel M. I., Mizzen A., Clin. Exp. Immunol., 121, 216-225 (2000).
19. Lin K.-Y., Guarnieri F. G., Staveley-O'Carroll K. F., Levitsky H. I., August J. T., Pardoll D. M., Wu T.-C., Cancer Res., 56, 21-26 (1996).
20. Ji H. X., Chang E. Y., Lin K.-Y., Kurman R. J., Pardoll D. M., Wu T.-C., Int. J. Cancer, 78, 41-45 (1998).
21. Thornburg C., Boczkowski D., Gilboa E., Nair S. K., J. Immunother., 23, 412-418 (2000).
22. Schäfer K., Müller M., Faath S., Henn A., Osen W., Zetgraf H., Benner A., Gissmann L., Jochmus I., Int. J. Cancer, 81, 881-888 (1999).
23. Resing M. E., Sette A., Bradt R. M. P., Ruppert J., Wenjtworth P. A., J. Immunol., 154, 5934-5943 (1995).
24. Van der Hulst J. M., Kwappenberg K. M. C., Hassane S., Franken K. L. M. C., Drijout J. W., Flenren G. J., Kenter D., Mtlief C. J. M., Offringa R., Van der Banderburg S. H., Cancer Res., 63, 636-641 (2003).
25. Murakami M., Gurski K. J., Marincola F. M., Ackland J., Steller M. A., Cancer Res., 59, 1184-1189 (1999).
26. Šmahel M., Šima P., Ludviková V., Vonka V., Virology, 281, 231-238 (2001).
27. Shi W., Bu P., Liu J., Polack A., Fisher S., Qiao L., J. Virol., 73, 7877-7881 (1999).
28. Wu T.-C., Guarnieri F. G., Staveley-O'Carroll K. F., Viscidi R. P., Levitsky H. I., Hedrick L., Cho K. R., August T., Pardoll D. M., Proc. Natl. Acad. Sci. U.S.A., 92, 11671-11675 (1995).
29. Korzeniewske C., Callewaert D. M., J. Immunol. Methods, 64, 313-320 (1983).
30. Decker T., Lohmann-Matthes M. L., J. Immunol. Methods, 115, 61-69 (1988).
31. Ma Y. W., Zhou X. S., Zhao Q. Z., Li Y. C., Biol. Pharm. Bull., 26, 137-140 (2003).
32. He Z., Wlazlo A. P., Kowalczyk D. W., Cheng J., Xiang Z. Q., Giles-Davis W., Ertl H. C., Virology, 270, 146-161 (2000).
33. Sundaram P., Tigelaa R. E., Xiao W., Brandsma J. L., Vaccine, 16, 613-623 (1998).
34. Kadish A. S., Ho G. Y. F., Burk R. D., Wang Y., Romney S. L., Ledwidge R., Angeletti R. H., J. Natl. Cancer Inst., 89, 1285-1293 (1997).
35. Lipford G. B., Bauer S., Wagner H., Immunology, 84, 298-303 (1995).